Why the study?
What are the principles and efficacy of chemotherapy agents in the treatment of prostatic cancer?
What are the principles and efficacy of chemotherapy agents in the treatment of prostatic cancer?
Single-agent chemotherapy shows some efficacy in prostate cancer, and the use of hormonal carriers like estramustine phosphate deserves further exploration.
Answers are grounded in this paper and cite their sources.
Single-agent chemotherapy may be considered in advanced prostate cancer; leaves open whether combinations or hormonal conjugates improve outcomes.
The efficacy of chemotherapy for prostatic cancer is difficult to evaluate owing to the low incidence of measurable indicator lesions and the resulting need for indirect response criteria. Although complete regressions remain exceptional, a number of agents, eg, doxorubicin and cisplatin have been shown to be effective in the treatment of this disease. So far, combinations of effective agents with or without concomitant hormone therapy have not proven to be more effective than single agents. Androgen priming has considerable theoretical appeal and deserves further consideration. A higher effectiveness of chemotherapeutic agents might be obtained by linkage to various carriers. Estramustine phosphate is an example of such a complex that has a cytotoxic effect in test systems in which estrogen has no effect and in patients with hormone-refractory prostatic cancer. The use of hormonal and other carriers that could increase the specificity of chemotherapeutic agents deserves extensive exploration.
No takes yet. Share an insight, caveat, or question.
Könyves et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: